The Dutch national inhaler care pathway for patients with asthma/COPD: a hybrid type III implementation study

Published: 17-06-2021 Last updated: 08-11-2023

The aim of this study is to identify barriers and facilitators for successful implementation of the care pathway, to ultimately inform national scale-up of the pathway.

Ethical reviewPositive opinionStatusRecruitment stoppedHealth condition typeRespiratory disorders NECStudy typeObservational non invasive

Summary

ID

NL-OMON26085

Source

Nationaal Trial Register

Brief title

LAN inhaler pathway

Condition

Respiratory disorders NEC

Synonym

Chronic Obstructive Pulmonary Disease, Asthma

Health condition

asthma, COPD

Research involving

Human

Sponsors and support

Primary sponsor: Lung Alliance Netherlands (LAN) and University Medical Center Groningen **Source(s) of monetary or material Support:** Multiple industry sources

Intervention

Other intervention

Explanation

Outcome measures

Primary outcome

Barriers and facilitators for optimal implementation of the national inhaler care pathway

Secondary outcome

Clinical outcomes: relievers/controller ratio, medication adherence, uniformity in inhaler devices, exacerbations. Qualitative outcomes: Implementation of inhaler care pathway elements, agreements between healthcare providers made, time investment, patient satisfaction, healthcare provider satisfaction

Study description

Background summary

Strategies to enhance inhaler technique and medication adherence to inhaled respiratory medication have been proven effective and cost-effective. In 2019, the Lung Alliance Netherlands (LAN) designed a national multidisciplinary care pathway for patients using inhaled medication by integrating these strategies. Yet, optimal implementation remains to be uncovered.

Study objective

The aim of this study is to identify barriers and facilitators for successful implementation of the care pathway, to ultimately inform national scale-up of the pathway.

Study design

This is a hybrid type III implementation study

Intervention

Inhaler care pathway implementation

Contacts

Public

University Medical Center Groningen Job Van Boven

+31503617893

Scientific

University Medical Center Groningen Job Van Boven

+31503617893

Eligibility criteria

Age

Adults (18-64 years) Adults (18-64 years) Elderly (65 years and older) Elderly (65 years and older)

Inclusion criteria

(i) patients >=18 years having asthma and/or COPD (ii) using inhaled medication for at least three months; (iii) understanding the Dutch language

Exclusion criteria

<18 years; not understanding Dutch

Study design

Design

Study phase: N/A

Study type: Observational non invasive

Intervention model: Single

Allocation: Non-randomized controlled trial

Masking: Open (masking not used)

Control: N/A , unknown

Primary purpose: Health services research

Recruitment

NL

Recruitment status: Recruitment stopped

Start date (anticipated): 01-07-2021

Enrollment: 500

Type: Actual

IPD sharing statement

Plan to share IPD: No

Ethics review

Positive opinion

Date: 12-11-2020

Application type: First submission

Review commission: nWMO adviescommissie UMC Groningen

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register ID

NTR-new NL9560

Other METC UMCG: METc 2020/593

Study results

Results posted: 06-11-2023

Actual enrolment: 602

Summary results

At least 104 general practitioners, 33 pulmonologists and 33 pharmacies were involved within the four pilot regions. A total of 602 patient questionnaires were completed, of which 159 were new patients and 432 patients with follow-up inhalation medication. After three rounds, there seemed to be tentative regional changes and improvements. Facilitators for good implementation were the set-up of the multidisciplinary training courses, and the interim measurements and associated feedback. The barriers of the implementation were: making and maintaining good cooperation agreements, and embedding the care pathway in the daily routine care. The care pathway has not yet been fully implemented within the pilot regions, but it has been well received so far: The regions have received training, multidisciplinary working groups have been set up, work agreements have been made, and local (and regional) changes have been made. Embedding the care pathway is the biggest bottleneck in the regions.

Baseline characteristics

N=602 patients included. 40.3% male; mean age (SD) 59.7 years \pm 17.2; Diagnosis: asthma: 43.6%; COPD: 31.7%; ACO: 15.5%;

Participant flow

Not applicable (single visit)

Adverse events

Not applicable

Outcome measures

Facilitators for good implementation were the set-up of the multidisciplinary training courses, and the interim measurements and associated feedback. The barriers of the implementation were: making and maintaining good cooperation agreements, and embeddin

First publication

20-04-2023

5 - The Dutch national inhaler care pathway for patients with asthma/COPD: a hybrid ... 16-06-2025